The Conversation (0)
Bellerophon to Present Clinical Data Supporting Actigraphy as a Clinically Meaningful Endpoint
Jan. 28, 2019 09:01AM PST
Biotech Investing
Bellerophon Therapeutics (Nasdaq:BLPH) a clinical-stage biotherapeutics company, today announced that data from the Company’s ongoing INOpulse Phase 2b clinical trial (iNO-PF) for the treatment of Pulmonary Hypertension associated with Interstitial Lung Disease (PH-ILD) that supports actigraphy as a clinically meaningful endpoint will be the subject of a poster presentation at the 13th Annual Pulmonary Vascular Research …
Bellerophon Therapeutics (Nasdaq:BLPH) a clinical-stage biotherapeutics company, today announced that data from the Company’s ongoing INOpulse Phase 2b clinical trial (iNO-PF) for the treatment of Pulmonary Hypertension associated with Interstitial Lung Disease (PH-ILD) that supports actigraphy as a clinically meaningful endpoint will be the subject of a poster presentation at the 13th Annual Pulmonary Vascular Research Institute World Congress on Pulmonary Vascular Disease, which will take place January 31 through February 3, 2019, in Barcelona, Spain.
As quoted in the press release:
Actigraphy (medical wearable continuous activity monitoring) provides highly sensitive objective real-world physical activity data that correlates to patient functional abilities and health outcomes. Bellerophon is currently utilizing actigraphy to evaluate multiple clinically meaningful activity parameters in the iNO-PF study. In addition, actigraphy is currently being utilized as the primary endpoint in several pivotal clinical trials in other cardiopulmonary indications, such as heart failure and Chronic Obstructive Pulmonary Disorder.
“Evaluating real-world physical activity in patients suffering from cardiopulmonary diseases provides invaluable insight in assessing disease progression and overall patient well-being,” said James Loyd, M.D., Professor of Medicine at Vanderbilt University Medical Center, an author of the poster to be presented and a principal investigator in the iNO-PF study. “Having enrolled more than 10 patients into the iNO-PF study, including the first patient into Cohort 2, I believe that actigraphy provides clinically meaningful data sensitive to functional change following treatment with INOpulse. Based on my experience and the clinical data generated to date, I am confident that INOpulse has the unique potential to become the first therapy to treat PH-ILD, a disease with a serious unmet medical need.”